ABSTRACT
Tem sido atribuído ao flavonóide kaempferitrina e ao alcalóide galegina efeito hipoglicêmico. Folha de Pterogyne nitens, por conter tais compostos, poderia ser antidiabética. Assim, avaliamos o efeito do tratamento com Pterogyne nitens a ratos diabéticos sobre níveis glicêmicos e parâmetros fisiológicos. Ratos diabéticos (50 mg estreptozotocina/Kg peso) foram tratados durante 32 dias, 2 vezes ao dia, por gavagem com extrato etanólico de folhas de Pterogyne nitens (76 mg/0,5 mL glicerina 10 por cento por rato) (DTPn). Grupos diabéticos controles foram tratados com: glicerina 10 por cento (0,5 mL) (DTG), insulina (2,5 U/0,3 mL) (DTI) e água (0,5 mL) (DTA). Semanalmente determinamos: peso corporal, ingestão hídrica e alimentar, volume urinário e nível glicêmico. Os resultados dos grupos DTPn, DTG e DTA foram diferentes do DTI para todos os parâmetros, ocorrendo ganho de peso corporal e redução dos demais parâmetros no DTI. O grupo DTPn apresentou resultados semelhantes aos DTG e DTA. Através dos resultados apresentados no grupo DTI, constatamos que o modelo de estudo foi adequado. Também concluímos que o extrato vegetal e a glicerina não melhoraram e nem exacerbaram o quadro diabético. Resta a possibilidade da planta promover melhoria do diabetes com diferente: dose do extrato, via de administração ou severidade do diabetes induzido.
Kaempferitrin (a flavonoid) and galegin (an alkaloid) have been indicated as hypoglycemic agents. Leaves of Pterogyne nitens, which contain both compounds, might be antidiabetic. We therefore treated diabetic rats with these leaves to observe the effects on their glycemia and physiological variables. Streptozotocin-diabetic rats were given ethanolic extract of the leaves (76 mg in 0.5 mL 10 percent glycerol) (DTPn), twice a day by gavage for 32 days. Diabetic controls were given 0.5 mL 10 percent glycerol (DTG), insulin (2.5 U in 0.3 mL) (DTI) or 0.5 mL water (DTA). During this treatment, we measured level of glycemia, the body weight, daily food and water intake and urine volume, once each week. The results for the DTPn, DTG and DTA groups all differed significantly from these for the DTI group. The latter exhibited greater body weights and lower physiological variables and glycemia than the groups DTPn, DTG and DTA, all of which gave similar results. From the data for DTI rats, we conclude that the study model was appropriate. Therefore, the plant extract (plus glycerol) neither improved nor worsened the diabetic state of the rats. It is possible that this plant might ameliorate diabetes experimental if the dose of extract, treatment route or severity of induced diabetes were altered.
ABSTRACT
OBJECTIVE: To assess the effect of a new feed soy product fermented by Enterococcus faecium and Lactobacillus jugurti on the serum lipid levels of rabbits with induced hypercholesterolemia. METHODS: Thirty-two rabbits were divided into 4 groups as follows: 1) control (C); 2) hypercholesterolemic (H); 3) hypercholesterolemic + fermented product (HPF); and 4) control + fermented product (CPF). The H and HPF groups were fed with a diet with 0.15 per cent (p/p) cholesterol in the first 15 days. C and CPF groups received regular food preparation. The HPF and CPF groups received 10 mL daily of the fermented 30 days. Blood samples were drawn at the beginning of the study and at the 15th and 30th days. Concentrations of total cholesterol, HDL-cholesterol, and triglycerides were analyzed. RESULTS: After 15 days, the HPF group showed a total cholesterol concentration lower (18.4 per cent) than that of the H group (p=0.05), but this difference disappeared after 30 days. No change was observed in total cholesterol levels of C and CPF groups. After 15 days, the HDL-cholesterol was higher (17.8 per cent) in the HPF group, but the triglyceride levels remained unchanged in all groups during the same period of time. CONCLUSION: The soy fermented product caused an 18.4 per cent reduction in total cholesterol and a 17.8 per cent increase in the HDL-fraction. It may, therefore, be a possible coadjutor in the treatment of hypercholesterolemia.